SUZHOU, China, Jan. 18, 2023, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present the design of 2 cohorts from a Phase I/IIa study of TST001, its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, in combination with Nivolumab plus Capecitabine and Oxaliplatin as first-line or with Nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer (TranStar102/TST001-1002).

Oct 24, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that Transcenta is invited to participate the 10th TEMTIA meeting in Paris, France, November 7 to 10and present preclinical data of TST003, Transcenta’s first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1.

SUZHOU, China, Oct. 14, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it will present two scientific posters at the 37th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston, MA, November 8-12, 2022: one related to Claudin18.2 and PD-L1 expression in gastric/gastro-esophageal adenocarcinoma, relevant for TST001 (Osemitamab) clinical development and the other on TST005 (PD-L1/TGF-β bifunctional antibody) trial in progress.

SUZHOU, China, July 28, 2022 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safety and efficacy data of dose expansion cohort from the phase I study of TST001, a humanized anti-Claudin18.2 monoclonal antibody, in combination with Capecitabine and Oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, which will be held on September 9-13, 2022. Details will be provided upon Embargo release later.

TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation. MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated thrombotic microangiopathy (HSCT-TMA). Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.

SUZHOU, China, April 28, 2022, Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts of TST001 and MSB0254 have been accepted by the 2022 annual meeting of American Society of Clinical Oncology (“2022 ASCO Annual Meeting”). The abstracts are named “A Phase I Study of TST001, a High Affinity Humanized Anti-CLDN18.2 Monoclonal Antibody, in Combination with Capecitabine and Oxaliplatin (CAPOX) as a First Line Treatment of Advanced G/GEJ Cancer” and “A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MSB0254 in Chinese Solid Tumor Patients” respectively.